Monday , November 25 2024
Home / Mike Norman Economics / A mysterious company’s coronavirus papers in top medical journals may be unravelling

A mysterious company’s coronavirus papers in top medical journals may be unravelling

Summary:
I've was debating hard with the C19 conspiracists and then this article turned up. Although I never did debate with them about this topic that much. The conspiracists think that Bill Gates and Big pharma closed this research down as it competed with the new medicines they are developing, but maybe there was just some kind of error? We will have to see.On its face, it was a major finding: Antimalarial drugs touted by the White House as possible COVID-19 treatments looked to be not just ineffective, but downright deadly. A study published on 22 May in The Lancet used hospital records procured by a little-known data analytics company called Surgisphere to conclude that coronavirus patients taking chloroquine or hydroxychloroquine were more likely to show an irregular heart rhythm—a known

Topics:
Mike Norman considers the following as important:

This could be interesting, too:

Matias Vernengo writes Milei’s Psycho Shock Therapy

Bill Haskell writes Population Growth Outcomes

Robert Vienneau writes Books After Marx

Joel Eissenberg writes Undocumented labor: solutions, not scapegoating

A mysterious company’s coronavirus papers in top medical journals may be unravelling

I've was debating hard with the C19 conspiracists and then this article turned up. Although I never did debate with them about this topic that much. The conspiracists think that Bill Gates and Big pharma closed this research down as it competed with the new medicines they are developing, but maybe there was just some kind of error? We will have to see.

On its face, it was a major finding: Antimalarial drugs touted by the White House as possible COVID-19 treatments looked to be not just ineffective, but downright deadly. A study published on 22 May in The Lancet used hospital records procured by a little-known data analytics company called Surgisphere to conclude that coronavirus patients taking chloroquine or hydroxychloroquine were more likely to show an irregular heart rhythm—a known side effect thought to be rare—and were more likely to die in the hospital.

Within days, some large randomized trials of the drugs—the type that might prove or disprove the retrospective study’s analysis—screeched to a halt. Solidarity, the World Health Organization’s (WHO’s) megatrial of potential COVID-19 treatments, paused recruitment into its hydroxychloroquine arm, for example. (Update: At a briefing on 3 June WHO announced it would resume that arm of the study.)


Kelly Servick, Martin Enserink, Science
Mike Norman
Mike Norman is an economist and veteran trader whose career has spanned over 30 years on Wall Street. He is a former member and trader on the CME, NYMEX, COMEX and NYFE and he managed money for one of the largest hedge funds and ran a prop trading desk for Credit Suisse.

Leave a Reply

Your email address will not be published. Required fields are marked *